Ralliant (NYSE:RAL) Cut to “Strong Sell” at Zacks Research

Zacks Research cut shares of Ralliant (NYSE:RAL) from a hold rating to a strong sell rating in a research report sent to investors on Monday,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. Barclays reduced their price target on shares of Ralliant from $60.00 to $52.00 and set an “overweight” rating on the stock in a research report on Monday. Royal Bank Of Canada reduced their target price on shares of Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a research report on Friday, February 6th. Morgan Stanley reissued an “overweight” rating and set a $45.00 price target on shares of Ralliant in a research note on Friday, February 6th. Vertical Research upgraded shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a research report on Friday, February 6th. Finally, Weiss Ratings downgraded Ralliant from a “hold (c)” rating to a “sell (d)” rating in a report on Thursday, February 5th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $50.50.

Ralliant Trading Down 0.6%

Shares of RAL stock opened at $42.78 on Monday. The company has a market capitalization of $4.83 billion and a P/E ratio of 21.83. Ralliant has a 12-month low of $37.27 and a 12-month high of $57.02. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38. The firm has a 50-day moving average price of $51.11 and a 200 day moving average price of $46.62.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, March 9th. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Ralliant’s payout ratio is presently 10.20%.

Insider Activity

In related news, Director Anelise Angelino Sacks acquired 2,000 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was acquired at an average price of $41.25 per share, for a total transaction of $82,500.00. Following the completion of the acquisition, the director owned 5,403 shares of the company’s stock, valued at $222,873.75. This trade represents a 58.77% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Kevin E. Bryant bought 1,250 shares of the business’s stock in a transaction on Friday, February 6th. The stock was bought at an average cost of $39.97 per share, for a total transaction of $49,962.50. Following the purchase, the director directly owned 4,653 shares of the company’s stock, valued at approximately $185,980.41. This trade represents a 36.73% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 5,795 shares of company stock valued at $232,405 in the last 90 days.

Institutional Trading of Ralliant

A number of institutional investors and hedge funds have recently modified their holdings of RAL. Danske Bank A S acquired a new position in Ralliant during the fourth quarter valued at approximately $25,000. Westfuller Advisors LLC bought a new position in shares of Ralliant during the third quarter worth $26,000. V Square Quantitative Management LLC acquired a new position in shares of Ralliant in the 4th quarter valued at $26,000. Allworth Financial LP lifted its holdings in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after acquiring an additional 293 shares in the last quarter. Finally, Palisade Asset Management LLC acquired a new position in Ralliant in the third quarter valued at about $26,000.

More Ralliant News

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Company insiders (directors and an SVP) bought shares this week, signaling management confidence and providing a support signal for some investors. Insider Buying Alert
• Positive Sentiment: Vertical Research upgraded RAL (reported by media), which can attract buyers and help stabilize demand. Vertical Research Upgrade
• Neutral Sentiment: Ralliant will present at Citi and Barclays investor conferences Feb. 17–18 — management may use these forums to clarify impairment drivers and outlook (could reduce uncertainty if handled well). Investor Conference Notice
• Neutral Sentiment: Some sell‑side firms trimmed price targets (Barclays, Citi, Oppenheimer et al.) — mixed analyst adjustments leave consensus still above current levels but reduce near‑term enthusiasm. Analyst Target Moves
• Negative Sentiment: Ralliant disclosed a $1.4B non‑cash goodwill impairment in its Test & Measurement segment and trimmed FY‑2026 guidance — a material accounting charge that directly pressured the stock and prompted analyst downgrades. Impairment / Guidance Notice
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Kessler Topaz, Kaplan Fox, Kirby McInerney, Bragar Eagel & Squire, etc.) have opened investigations into the timing and disclosure around the impairment and dividend — this raises litigation, regulatory and reputational risk. Levi & Korsinsky Alert
• Negative Sentiment: Short interest jumped ~58.7% in January (~3.75M shares, ~3.3% of float), increasing bearish positioning that can amplify downside and intraday volatility.
• Negative Sentiment: Independent downgrades (e.g., Zacks strong‑sell, Weiss Ratings cut) add selling pressure and can limit buyers until uncertainty eases. Zacks

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.